Skip to content
Screener

D&A at other companies

Danaher logo
DanaherDHR
$196M+5.9%
Azenta logo
AzentaAZTA
$13.58M-7.8%
Agilent Technologies logo
Agilent TechnologiesA
$67M-8.2%
Illumina logo
IlluminaILMN
$51M-1.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$6.1M+32.6%
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$9.66M+23.7%

Segments

By segment

See full
Reportable Segment$6.41M+0.2%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(in thousands)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Research and development expenses[1]17,36619,95232,71238,078
Selling, general and administrative expenses[1]59,25547,298117,03493,786
Litigation settlement costs, net of recoveries7,2057,205
Depreciation and amortization6,4146,40212,60812,784
Stock-based compensation expense18,93620,32832,20932,319
Total costs and expenses$156,578$134,353$293,176$257,711
Loss from operations$(45,863)$(41,560)$(78,763)$(76,205)
Interest income$1,710$2,801$3,885$6,041

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's D&A?
Twist Bioscience Corporation (TWST) reported D&A of $6.41M in Q1 2026.
How has Twist Bioscience Corporation's D&A changed year-over-year?
Twist Bioscience Corporation's D&A increased by 0.2% year-over-year, from $6.4M to $6.41M.
What is the long-term trend for Twist Bioscience Corporation's D&A?
Over 4 years (2021 to 2025), Twist Bioscience Corporation's D&A has grown at a 26.4% compound annual growth rate (CAGR), from $9.75M to $24.85M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Twist Bioscience Corporation's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude